Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 14Completed 13Withdrawn 3Unknown 3Terminated 2Not yet recruiting 2Active not recruiting 2No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2

Conditions

Neuroendocrine Tumors 2von Hippel-Lindau Disease 1Paraganglioma 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 1 1Meningioma 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × gallium Ga 68 dotatate × Clear all
NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
4 enrolled
CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡